SCHEDULE: Vanguard Discloses 7.04% Stake in Kiniksa Pharmaceuticals
Beneficial Ownership Report (Schedule 13G Amendment)
The Vanguard Group has reported a 7.04% beneficial ownership stake in Kiniksa Pharmaceuticals International Plc common stock as of September 30, 2025.
Summary
- The Vanguard Group, an investment adviser, reported beneficial ownership of 3,063,135 shares of Kiniksa Pharmaceuticals International Plc common stock.
- This represents 7.04% of the total class of securities.
- Vanguard holds sole dispositive power over 3,004,905 shares and shared dispositive power over 58,230 shares.
- Vanguard has shared voting power over 34,807 shares and no sole voting power.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a routine disclosure of beneficial ownership by a large institutional investor. While a significant stake by Vanguard can be viewed positively, the filing itself does not contain performance data or strategic updates to warrant a strong positive or negative sentiment.
Positives
- A significant institutional investor, The Vanguard Group, holds a substantial 7.04% stake, which may indicate long-term confidence in Kiniksa Pharmaceuticals.
- The holding is for investment purposes in the ordinary course of business, not for control, suggesting a passive and potentially stable investment.
Negatives
- No specific negative information is disclosed in this beneficial ownership report.
Risks
- No specific risks related to Kiniksa Pharmaceuticals' operations or financial health are disclosed in this beneficial ownership report, as it focuses solely on Vanguard's ownership stake.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which may influence investor perception and confidence.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement (as of which beneficial ownership is reported) |
| 10/31/2025 | Signature date of the filing by The Vanguard Group |
Keywords
Vanguard Group, Kiniksa Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.